The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

"Similar trends" that fell short of statistical significance were also seen when JAK inhibitors were compared with less popular types of biologic therapy, such as interleukin (IL)-6 inhibitors ...

Janus kinase (JAK) inhibitors are an important treatment option ... increased risk of cardiovascular diseases and certain types of cancer, must be carefully considered. Important new aspects ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

JAK inhibitors, such as ruxolitinib cream and abrocitinib, present promising alternatives to existing therapies for managing moderate to severe atopic dermatitis, offering effective treatment options.

TIAs seemed to drive the increased MACE rates for anti-TNFs and other biologics versus JAK inhibitors. No difference in rates of stroke were seen among the three drug types, and MIs were only ...

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred.

Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors ... IL-23, and type I interferons, thereby clinically improving psoriatic plaques.

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...